OBR and MDoutlook are pleased to share excerpts from the most recent MDoutlook’s OncoPolls™ from ASCO 2015. This report highlights certain presentations concerning the anti-PD-1 / PD-L1 antibody-based Immune Checkpoint Inhibitors and other new agents in Gastrointestinal cancers. This research is based on separate surveys in non-Colorectal Gastrointestinal cancer and Colorectal cancer. The full complimentary report is available through MDoutlook per details below.
Expected Impact of Immune Checkpoint Blockade Antibodies in Non-CRC GI Cancer
Perceived Value of Immune Checkpoint Blockade Antibodies in Non-CRC GI Cancer
Multi-Factorial Impact of Targeted Agents as a Therapeutic Strategy for BRAF-Mutated mCRC
Perceived Value of Immune Checkpoint Blockade Antibodies in mCRC
Expected Impact of PEGH20 on Pancreatic Cancer Treatment Landscape
Expected Clinical Impact of PEGH20
Regorafenib in Advanced Gastric and Gastric Esophageal Junction Cancer: Expected to be Widely Used
Expected use of regorafenib in advanced G/GEJ cancer
Impact of Abstract# LBA100: Expected Usage of Testing for MMR Deficiency and Treatment with Immune Checkpoint Blockade Antibodies in MMR-Deficient mCRC
Conclusions: Immediate Impact of 2015 ASCO Presentations on Clinical Practice
Non-CRC GI Cancers
Metastatic Colorectal Cancer
For a more detailed analysis report, please click here to download the full report.
Submitted by Robert Stephan, Sr. Director Medical Services and Strategy, and Jan Heybroek, President MDoutlook.
You must be logged in to post a comment